Description:
Delegates attending this course will benefit from an introductory overview of the terminology and classification of cancer and principle issues in its treatment. Commonly available anti-cancer drugs will be reviewed, particularly in relation to mode of action, dose intensity and chemotherapy regimes. This will lead on to a detailed study of the range of side effects commonly and uncommonly experienced by cancer patients undergoing chemotherapy treatment. Quality of life issues will also be discussed in terms of overall assessment and interpretation of results.
Detailed consideration will then be given to the treatment of lung, breast, upper GI, colorectal, ovarian, prostate and skin cancers. Each of these sessions, presented by clinicians active in these areas, will focus on overall patient presentation and management, diagnosis and staging. Our experts will then lead delegates in interactive group discussions of key issues relating to effective management of each of these tumor types.
The limitations of currently available cytotoxic drugs are well known. For this reason delegates will find the course includes in-depth discussions of new drug development and identification of new pharmacological targets of particular interest and value. Clinical trial design issues in early and randomised trials will also be covered.
Topics include:
Cancer: Terminology and classification
Introduction to anti-cancer drugs and side effects
Side effects of chemotherapy and radiotherapy
New developments in cancer therapy
Introduction to the major tumor types: breast, lung, melanoma, upper GI, colorectal, ovarian and prostate cancer
Clinical trial issues in oncology
Course Instructors:
Jeffrey Crawford, MD
George Barth Geller Professor for Research in Cancer
Chief of Medical Oncology
Duke University Medical Center
North Carolina, USA
Nancy A Dawson, MD
Professor of Medicine
Director, Genito-Urinary Medical Oncology
Georgetown University Hospital
Washington, USA
Stergios Moschos, MD
Clinical Associate Professor of Medicine
University of North Carolina at Chapel Hill
North Carolina, USA
Bert O’Neil, MD
Associate Professor in Clinical Research
UNC Lineberger Comprehensive Cancer Center
North Carolina, USA
Jeffrey Peppercorn, MD
Assistant Professor of Medicine
Division of Medical Oncology
Duke University Medical Center
North Carolina, USA
Russell Schilder, MD
Chief, Gynecologic Medical Oncology
Thomas Jefferson University
Philadelphia, USA
Who Should Attend: Healthcare’s courses are designed for both medical and non-medical staff within the pharmaceutical industry. This course is suitable for clinical research, medical information, regulatory affairs, biometrics and strategic marketing personnel.
Venue/Administrative Details:
Accomodation costs are not included.
The registration fee at our VIP Discount Rate is $3,885 (regular rate $4,586 USD). This includes lunch and refreshments throughout the day. Accommodation costs are not included. Delegates can register on-line or by completing the booking form and returning it together with the appropriate payment to Cambridge Healthtech Institute. Please retain a copy of the booking form for your records. Details of the venue will be provided upon registration.
Schedule:
May 23, 2012:
8:15 am – 5:30 pm
May 24, 2012:
8:15 am – 3:15 pm
* Please note: This course is organized by Healthcare Education Services and is being co-marketed by Cambridge Healthtech Institute (CHI). By registering through CHI, you save 15% off the registration rate charged by Healthcare Education Services. No refund/credit of registration fee will be made for any cancellations received less than 20 working days prior to the date of the course. Cancellations made more than 20 working days prior to course date will incur a $175 administration fee. Substitutions may be made at any time. If Healthcare cancels or postpones this event, the registration fee will be refunded. Healthcare will not accept liability for any other costs. Healthcare reserves the right to amend the content and timing of all courses. Your details will be entered onto our database and we may, from time to time, advise you of other products that may be of interest to you. If you do not wish to receive this information then please let us know.